0 likes | 13 Views
Explore the transformative impact of Encorafenib at Impomed Healthcare, where game-changing strides redefine the rules for metastatic colorectal cancer (mCRC). Our commitment is evident as we showcase Encorafenib's revolutionary approach, offering renewed hope and improved outcomes for patients. Experience a paradigm shift in cancer care with personalized treatments that set new standards. Discover how Encorafenib, in collaboration with Impomed Healthcare, is rewriting the narrative for mCRC,<br>For more information click on this link:- https://www.impomedhealthcare.com/<br>
E N D
ENCORAFENIB Home | Cancer | Solid Tumors | ENCORAFENIB ENCORAFENIB Capsules Description Composition Dosage Indications BRAFTOVI (encorafenib) is a kinase inhibitor. BRAFTOVI (encorafenib) capsules for oral use contain 50 mg or 75 mg of encorafenib with the following inactive ingredients: copovidone, poloxamer 188, microcrystalline cellulose, succinic acid, crospovidone, colloidal silicon dioxide, magnesium stearate (vegetable origin). The capsule shell contains gelatin, titanium dioxide, iron oxide red, iron oxide yellow, ferrosoferric oxide, monogramming ink (pharmaceutical glaze, ferrosoferric oxide, propylene glycol). Copyright © 2024 ImpoMed Convert web pages and HTML files to PDF in your applications with the Pdfcrowd HTML to PDF API Printed with Pdfcrowd.com